Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications COVID 2019 infections; Lymphopenia
  • Focus Therapeutic Use
  • Acronyms ILIAD-7-FR
  • Sponsors Revimmune SAS

Most Recent Events

  • 06 Apr 2022 Status has been changed to discontinued.
  • 13 Jan 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2021.
  • 13 Jan 2021 Planned primary completion date changed from 30 Oct 2020 to 30 Jul 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top